Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.
about
Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data.Review article: the treatment of functional abdominal bloating and distension.Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome.Partial reinforcement, extinction, and placebo analgesia.An Evidence-Based Look at Misconceptions in the Treatment of Patients with IBS-DPlacebo responses in patients with gastrointestinal disordersIrritable bowel syndrome: diagnosis and management.Guidelines on the irritable bowel syndrome: mechanisms and practical management.New therapeutic option for irritable bowel syndrome: serum-derived bovine immunoglobulinEvidence-based clinical practice guidelines for irritable bowel syndrome.Benefits from long-term treatment in irritable bowel syndrome.Targeted therapies for diarrhea-predominant irritable bowel syndrome.The placebo response in functional bowel disorders: perspectives and putative mechanisms.Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS.Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trialsDrugs affecting visceral sensitivity: ready for the prime time?Systematic review: the efficacy of treatments for irritable bowel syndrome--a European perspective.Systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome--a European perspective.Serotonin receptor modulators in the treatment of irritable bowel syndrome.Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.Recent developments in the therapy of irritable bowel syndrome.New treatments for irritable bowel syndrome in womenA 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program.Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles.Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis.Alosetron: an effective treatment for diarrhea-predominant irritable bowel syndrome.Efficacy of otilonium bromide in irritable bowel syndrome: a pooled analysisPharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome.Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis.Evaluating the functional net value of pharmacologic agents in treating irritable bowel syndrome.American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation.Placebo effects and their determinants in gastrointestinal disorders.Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS.Recommendations for pharmacological clinical trials in children with irritable bowel syndrome: the Rome foundation pediatric subcommittee on clinical trials.A Randomized Controlled Trial Comparing the Low FODMAP Diet vs. Modified NICE Guidelines in US Adults with IBS-D.Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial.A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.Reports of "satisfactory relief" by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement.Evolution of clinical trials for irritable bowel syndrome: issues in end points and study design.
P2860
Q31036400-09ABBC57-8A8E-4BA5-9DA4-A4BA2A60FAE8Q33450132-F5E8A87F-0316-4513-9E8F-56CCF11DC940Q33451900-D391C30B-3505-41AB-A3CD-2C1D35BFC9ADQ33630729-03EAF4A5-B94C-44B8-9257-96500EAEC27DQ33667183-39D36081-2CFA-4D80-819A-2C730492D2C5Q34098616-E97A679F-EBF3-4409-9578-E15A30882044Q34334525-79123D36-734D-45C1-9CAB-3A0E82D5B27CQ34626602-57AC4FCE-F21E-446F-BE35-4838EAD23C84Q35188643-BDDB8BC5-316D-4EF9-BF30-C2F0DAA92D0EQ35513973-79820542-EC05-43AB-A896-8D0A42791C53Q35681391-631228A3-94C0-4A51-996B-FB124EB7E882Q36065945-CC4854B0-42FB-49A7-BFAF-5B1A07D23CD8Q36139392-B71DED27-0A02-4697-B396-6157CBA3877DQ36297736-5EE1B71C-B194-45A3-A521-FD8295E9789AQ36307366-8611FE4D-D8FA-4819-92BA-21990ECDB70CQ36478102-541A5090-2AE7-4C22-99C4-953F0CD863DDQ36536707-ED97B39B-BB9A-4B1F-A56E-30AD92D6F1A1Q36536709-05AAC504-9E41-43D7-995F-22DB855ED374Q36822923-294F0C49-22F7-4CB2-8F7B-0360545635E0Q36983944-D85649C5-AD00-4DC7-88F6-EEA2A6DD6C9BQ37071175-E009F476-06E5-47D3-9A20-A66B0123851FQ37120300-81DEB157-4364-48D0-80B5-B30644A3A5F4Q37130608-7D46AA7D-CDAA-475B-9BD6-5BC0CC054B38Q37164063-F4AAEA28-F68F-4BB8-A9A5-F220872D33F1Q37496549-02AC9875-CDB4-44A6-BA0F-9A3ED68E388BQ37608344-34AF9952-17F1-4601-848A-340CEBAB0996Q37638787-9CD263FA-3323-492D-AEF4-F11E85A7330FQ37954521-84359FEC-BC51-4886-AE7F-8D97EB4D2D62Q38011936-009873B7-F840-4BAB-8BAB-21A885DAA5ADQ38194631-5C6E775E-50B0-48BB-9D1B-7EA1FB76B5A1Q38236812-05CCAD99-6C03-4271-92D8-E4486ADBBD4BQ38551120-6A4E9F3E-1A2E-4F1E-ADB1-0BA9C872C0F5Q38630721-06F14F34-EDD1-4EC6-B383-DED9FE31A8F6Q38675489-A02AEC02-8D64-41F7-8AF8-68C5B0888EA2Q38914226-496F88AC-3955-4D1E-91FA-3A8DF6101F8EQ39166286-0C3B85D6-926E-4266-AE55-D7D48C948F29Q39319919-998452E4-6C1C-474A-80AF-EE17E914795DQ39335358-EED776E5-4167-445A-812B-16C0BD4A761CQ39353092-1001343A-F189-44D8-9017-6001E7E7D526Q39885291-EE1C9ACC-F593-45E1-A25A-EDBC49CC75BC
P2860
Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.
description
2004 nî lūn-bûn
@nan
2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Long-term safety and efficacy ...... nant irritable bowel syndrome.
@ast
Long-term safety and efficacy ...... nant irritable bowel syndrome.
@en
Long-term safety and efficacy ...... nant irritable bowel syndrome.
@nl
type
label
Long-term safety and efficacy ...... nant irritable bowel syndrome.
@ast
Long-term safety and efficacy ...... nant irritable bowel syndrome.
@en
Long-term safety and efficacy ...... nant irritable bowel syndrome.
@nl
prefLabel
Long-term safety and efficacy ...... nant irritable bowel syndrome.
@ast
Long-term safety and efficacy ...... nant irritable bowel syndrome.
@en
Long-term safety and efficacy ...... nant irritable bowel syndrome.
@nl
P2093
P2860
P1476
Long-term safety and efficacy ...... nant irritable bowel syndrome.
@en
P2093
Allison Northcutt
Amy T Heath
Eric G Carter
George E Dukes
Vanessa Z Ameen
William D Chey
William Y Chey
P2860
P304
P356
10.1111/J.1572-0241.2004.30509.X
P407
P577
2004-11-01T00:00:00Z